Karl Lauterbach, about dts
Karl Lauterbach, about dts

Lauterbach criticizes the US government buying up Remdesivir

The SPD health expert Karl Lauterbach has sharply criticized the US government's purchase of the majority of the planned production of the promising drug Remdesivir by September.

"This is an extremely unfriendly act," said Lauterbach the "editorial network Germany" (Thursday editions). "If medication is secured in this way, it is an alarm signal and a cause for concern," he added.

The EU urgently needs to clarify how it will respond. "This is a foretaste of what to expect with a vaccine," warned the health expert. "If there is no second wave of pandemics, the remdesivir reserves in Germany are sufficient and there is no cause for concern." However, one does not know how the pandemic will develop and when a vaccine will be available, said Lauterbach. For example, there is a risk that the virus will mutate and become more dangerous. Medicines to treat the severe courses are therefore indispensable.